Table Graph
   

Non replicating viral vector - versus vaccines - for COVID-19 prophylaxis (excluding children) pdf   xlsx method abbreviations

Outcome Relative effect 95%CI LoD Trt. better when I2 k (RCT/OBS) Bayesian probability Overall ROB Publication bias Degree of certainty Endpoint importance Published MA

efficacy endpoints 00

safety endpoints 00

adverse events 1.14 [0.89, 1.46]< 10%2 studies (2/-)14.7 %NAnot evaluable non important-
intracranial hemorrhage 1.73 [0.18, 16.71]< 10%3 studies (3/-)31.8 %NAnot evaluable non important-
ischemic stroke 1.46 [0.17, 12.52]< 10%3 studies (3/-)36.6 %NAnot evaluable non important-
Myocardial infarction 2.39 [0.39, 14.69]< 10%4 studies (4/-)17.5 %NAnot evaluable non important-
pulmonary embolism 1.73 [0.18, 16.71]< 10%3 studies (3/-)31.8 %NAnot evaluable non important-
serious adverse events (SAE), any 1.53 [0.25, 9.36]< 10%1 study (1/-)32.3 %NAnot evaluable non important-
venous thromboembolism 1.82 [0.23, 14.13]< 10%3 studies (3/-)28.5 %NAnot evaluable non important-

LoD: level of statistical demonstration: Statistically conclusive: statistically significant with a strict control of overall risk of type 1 error (statistically demonstrated), does not take into account the risk of bias; suggested: nominally statistically significant but without a strict control of overall risk of type 1 error; inconclusive: not nominally statistically significant; safety concerns;
Bayesian probability: Bayesian posterior probability of treatment effect (computed with a noninformative prior); ROB: risk of bias; k: number of studies; published MA: number of published meta-analysis on the same topic; degree of certainty adapted from GRADE. Trt. better when: indicates when the relative treatment effect shows that the studied treatment is better than control.



 

- About us - Contact us - Method - RSS Made with in Lyon - Credits - Privacy policy - Licence Creative Commons